What is the purpose of this 8-K filing?

This 8-K filing announces that Gilead Sciences, Inc. has entered into a material definitive agreement, specifically an Agreement and Plan of Merger, to acquire Immunomedics, Inc. It outlines the terms of the acquisition, which involves a cash tender offer and a subsequent merger.

What is the offer price for Immunomedics shares and how will the transaction be completed?

Gilead Sciences will commence a tender offer to purchase all outstanding shares of Immunomedics for $88.00 per share in cash. Following the successful tender offer, a merger will take place where Immunomedics will become a subsidiary of Gilead, with remaining shareholders receiving the same $88.00 per share in cash.

What are the key conditions that need to be met for this deal to close?

The transaction is subject to customary closing conditions, including the tender of a number of shares representing more than 50% of Immunomedics' outstanding stock, the expiration or termination of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act, and the absence of any governmental laws or orders prohibiting the transaction.

Are there any provisions for Immunomedics to consider other offers?

Immunomedics has agreed to customary 'no-shop' restrictions, limiting its ability to solicit or negotiate alternative acquisition proposals. However, under certain specific circumstances, Immunomedics may engage with third parties regarding a 'Superior Offer' if its board determines it to be in the company's best interest, and if failing to do so would be inconsistent with their fiduciary duties. If Immunomedics terminates the agreement to accept a superior offer, a termination fee of approximately $732.1 million would be payable.

GILD 8-K: Material Agreements

Summary

Gilead Sciences, Inc. (GILD) announced a significant material definitive agreement to acquire Immunomedics, Inc. through a tender offer and subsequent merger. Gilead, via its subsidiary Maui Merger Sub, Inc., will commence a tender offer to purchase all outstanding shares of Immunomedics common stock for $88.00 per share in cash. This acquisition, valued at approximately $88.00 per share, represents a substantial cash outlay for Gilead and is a strategic move to bolster its oncology pipeline, particularly with Immunomedics' promising drug, Trodelvy. The transaction is subject to customary closing conditions, including a minimum tender of over 50% of Immunomedics' shares and regulatory approvals, such as HSR clearance. Following the successful tender offer, a merger will be completed, with Immunomedics surviving as a subsidiary of Gilead. The agreement includes customary provisions like "no-shop" clauses for Immunomedics, with a specified termination fee payable under certain circumstances. Investors should note that this announcement signifies the intent and structure of the deal; detailed terms and further disclosures will follow in subsequent filings.

Key Highlights

1Gilead Sciences is acquiring Immunomedics, Inc. via a cash tender offer followed by a merger.
2The offer price is $88.00 per share in cash.
3The transaction is valued at approximately $88.00 per share for Immunomedics' common stock.
4The deal is structured as a tender offer by Gilead's subsidiary, Maui Merger Sub, Inc., for all outstanding shares.
5Key closing conditions include a minimum tender of over 50% of Immunomedics' shares and antitrust (HSR) approval.
6Immunomedics has agreed to customary 'no-shop' restrictions, with a termination fee of approximately $732.1 million applicable under specific circumstances.
7This acquisition is expected to enhance Gilead's oncology portfolio, notably with Immunomedics' drug Trodelvy.

GILEAD SCIENCES, INC. 8-K Report, Material Agreement (Sep 14, 2020)

Summary

Key Highlights

Frequently Asked Questions